Agios Pharmaceuticals, Inc. (0HB0.L)
USD 41.74
(-0.05%)
USD 41.74
(-0.05%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 56.98 Million USD | -33.47% |
| 2022 | 85.65 Million USD | -11.78% |
| 2021 | 97.09 Million USD | -7.7% |
| 2020 | 105.19 Million USD | -7.45% |
| 2019 | 113.66 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 48.76 Million USD | -28.66% |
| 2024 Q3 | 16.31 Million USD | -66.53% |
| 2024 Q1 | 68.34 Million USD | -5.07% |
| 2023 Q3 | 75.49 Million USD | -4.37% |
| 2023 FY | 71.99 Million USD | -15.95% |
| 2023 Q4 | 71.99 Million USD | -4.64% |
| 2023 Q1 | 82.33 Million USD | -3.88% |
| 2023 Q2 | 78.94 Million USD | -4.12% |
| 2022 Q3 | 88.92 Million USD | -2.46% |
| 2022 Q2 | 91.16 Million USD | -3.63% |
| 2022 Q1 | 94.6 Million USD | -2.56% |
| 2022 FY | 85.65 Million USD | -11.78% |
| 2022 Q4 | 85.65 Million USD | -3.67% |
| 2021 Q2 | 101.9 Million USD | -1.64% |
| 2021 Q4 | 97.09 Million USD | -2.06% |
| 2021 Q3 | 99.13 Million USD | -2.72% |
| 2021 FY | 97.09 Million USD | -7.7% |
| 2021 Q1 | 103.6 Million USD | 5.95% |
| 2020 Q3 | 358.22 Million USD | 1.39% |
| 2020 FY | 105.19 Million USD | -7.45% |
| 2020 Q4 | 97.78 Million USD | -72.7% |
| 2020 Q1 | 104.58 Million USD | -2.03% |
| 2020 Q2 | 353.32 Million USD | 237.85% |
| 2019 Q2 | 110.07 Million USD | 66.76% |
| 2019 FY | 113.66 Million USD | 0.0% |
| 2019 Q4 | 106.74 Million USD | -1.25% |
| 2019 Q3 | 108.09 Million USD | -1.8% |
| 2019 Q1 | 66 Million USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 36.53 Million USD | -55.978% |
| Dynavax Technologies Corporation | 256.91 Million USD | 77.818% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -37.231% |
| Perrigo Company plc | 4.07 Billion USD | 98.601% |
| Illumina, Inc. | 2.26 Billion USD | 97.481% |
| Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.837% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -5598.8% |
| Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.404% |
| IQVIA Holdings Inc. | 14.23 Billion USD | 99.6% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 67.202% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 97.892% |
| Unity Biotechnology, Inc. | 26.99 Million USD | -111.145% |
| Waters Corporation | 2.35 Billion USD | 97.581% |
| Biogen Inc. | 7.33 Billion USD | 99.223% |
| Sangamo Therapeutics, Inc. | 38.1 Million USD | -49.559% |
| Evolus, Inc. | 126.54 Million USD | 54.967% |
| Adicet Bio, Inc. | 17.7 Million USD | -221.912% |
| Cara Therapeutics, Inc. | 43.16 Million USD | -32.018% |
| bluebird bio, Inc. | 330.32 Million USD | 82.748% |
| Esperion Therapeutics, Inc. | 540.94 Million USD | 89.465% |
| FibroGen, Inc. | 170.45 Million USD | 66.567% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 97.916% |
| Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -172.876% |
| Homology Medicines, Inc. | 44.05 Million USD | -29.359% |
| Geron Corporation | 85.89 Million USD | 33.657% |
| Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 97.624% |
| Amicus Therapeutics, Inc. | 445.05 Million USD | 87.195% |
| Myriad Genetics, Inc. | 145 Million USD | 60.698% |
| Viking Therapeutics, Inc. | 1.26 Million USD | -4422.857% |
| Intellia Therapeutics, Inc. | 115.34 Million USD | 50.594% |
| Zoetis Inc. | 6.8 Billion USD | 99.162% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -1194.593% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 97.371% |
| BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 94.974% |
| Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 92.951% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -56.892% |
| Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 96.079% |
| Atara Biotherapeutics, Inc. | 57.87 Million USD | 1.528% |
| Verastem, Inc. | 41.55 Million USD | -37.132% |
| Nektar Therapeutics | 230.4 Million USD | 75.266% |
| Axsome Therapeutics, Inc. | 186.37 Million USD | 69.422% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1753.871% |
| Sarepta Therapeutics, Inc. | 1.39 Billion USD | 95.92% |
| OPKO Health, Inc. | 326.56 Million USD | 82.549% |
| Exelixis, Inc. | 189.94 Million USD | 69.997% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 86.697% |
| Corcept Therapeutics Incorporated | 151 Thousand USD | -37640.397% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 138.4 Million USD | 58.826% |
| Imunon, Inc. | 1.13 Million USD | -4902.05% |
| Blueprint Medicines Corporation | 774.12 Million USD | 92.638% |
| Insmed Incorporated | 1.2 Billion USD | 95.267% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 96.199% |
| TG Therapeutics, Inc. | 110.79 Million USD | 48.564% |
| Incyte Corporation | 38.28 Million USD | -48.844% |
| Emergent BioSolutions Inc. | 877.5 Million USD | 93.506% |